How to Qualify for Ozempic: BMI Rules, Diabetes Criteria, PA

Ozempic is FDA approved for heart risk and type 2 diabetes, and kidney disease in people with type 2 diabetes; you qualify when your diagnosis matches one of those uses. Health plans then add their own rules before they pay. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Active ingredient: semaglutide
How it is taken: weekly injection
Approved for: Heart risk and type 2 diabetes, and kidney disease in people with type 2 diabetes
Best result (STEP 1): 14.9% weight loss

Ozempic: the short version

How long it lasts in your body

Its half-life is about 1 week: after 7 d half is gone, and five half-lives (35 d) leave about 3%

Weight lost in the main trial

Results for type 2 diabetes in SUSTAIN 1 over 30 weeks: 4.7 kg lost, versus 1.2 kg on placebo.

Prices as time goes on

Prices by month in US dollars: the list price plus self-pay offers. Every figure comes from the maker's price page

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Who qualifies for Ozempic
Who sets the rule	Who qualifies
FDA label	Used with diet and exercise, it brings blood sugar down for adults with type 2 diabetes
FDA label	For adults with heart disease and type 2 diabetes, it lowers the risk of heart-related death, heart attack, and stroke
FDA label	This medicine reduces the risk of kidney disease getting worse, kidney failure, and death related to the heart in adults with both type 2 diabetes and chronic kidney disease.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	the first step is a diet and activity program lasting 6 months

Sources listed here: aetna.com, plus the FDA label (DailyMed)

Results from weight loss trials

This group has no trial for Ozempic itself. The trials cover brands that use the same ingredient.

Trials using the same ingredient (semaglutide)
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Source for the trial: STEP 1 (FDA label (DailyMed))

What is different for weight loss?

Eligibility points from the Ozempic label
What changes	What the label says
Risk of Thyroid C-Cell Tumors	In rodents, it caused thyroid C-cell tumors. It is not known whether it causes the same tumors in people. Not for people whose personal or family history includes medullary thyroid cancer (MTC), or who have MEN 2.

Note on sources: FDA label (DailyMed), taken from the FDA labels

These warnings come from the FDA label (DailyMed).

Coverage for weight loss

Medicare Part D will not cover a GLP-1 when it is used only for weight loss.

In areas where Medicaid covers weight-loss GLP-1s, prior authorization is usually required.

Sources: humana.com, KFF.

More weight loss choices

GLP-1 medicines and eligibility
Medicine	For eligibility	How it is taken	Trial result
Ozempic	Heart risk and type 2 diabetes, and kidney disease in people with type 2 diabetes	weekly injection	Not listed
Wegovy	Weight loss, heart risk and MASH liver disease	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Type 2 diabetes and heart risk	daily tablet	Not listed
Mounjaro	Type 2 diabetes and heart risk	weekly injection	Not listed
Zepbound	Weight loss and sleep apnea	weekly injection	20.9% weight loss
Foundayo	Weight loss	daily tablet	11.1% weight loss
Trulicity	Type 2 diabetes and heart risk	weekly injection	Not listed
Saxenda	Weight loss	daily injection	7.4% weight loss
Victoza	Type 2 diabetes and heart risk	daily injection	Not listed
Byetta	Type 2 diabetes	twice-daily injection	Not listed